$SOHU

SOHU.COM REPORTS SECOND QUARTER 2026 UNAUDITED FINANCIAL RESULTS

Sohu.com Limited (NASDAQ: SOHU) reported Q2 2026 unaudited results. Total revenue was $136m, up 7% YoY and down 4% QoQ. GAAP net income was $0.2m after a ~$13m tax expense reversal; non-GAAP net income was $0.5m. The board amended its ADS repurchase program to open-ended; $124m spent on 9.4m ADS as of Aug 6. Q3 guidance: marketing $14m-$15m, online games $105m-$115m, GAAP/non-GAAP net loss $13m-$23m.

Original reporting
Published Aug 10, 2026, 5:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 6:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SOHU.COM REPORTS SECOND QUARTER 2026 UNAUDITED FINANCIAL RESULTS — source image
Decision brief

The 30-second read

$SOHUNeutralMed
01

Why it matters

Traders can update near-term expectations using the disclosed Q2 revenue mix, operating loss/profit metrics, and the explicit Q3 ranges for marketing services, online games, and GAAP/non-GAAP net losses. The open-ended repurchase authorization may support downside but does not remove the fundamental revenue trajectory risk embedded in guidance.

02

Market read

A full earnings-and-guidance print with explicit Q3 ranges plus a repurchase-program change is a tradable catalyst for SOHU, with sentiment split between Q2 outperformance and Q3 decline expectations.

03

What to watch

Online game revenues were down sequentially and the Q3 outlook implies a sizable year-over-year decline, which could dominate valuation despite the buyback authorization.

Relevance 8/10Novelty 7/10Timing: pre-market today (Aug 10, 2026) earnings and Q3 guidance release

Background

Sohu.com Limited (SOHU) released unaudited Q2 2026 financial results and provided Q3 2026 revenue and net loss guidance, alongside an amendment to its ADS repurchase program.

Company-level read

Ticker impact

$SOHUNeutralMedium confidence
Context

Sohu reported Q2 2026 results and updated Q3 guidance, including marketing and online game revenue ranges and expected GAAP/non-GAAP net losses.

Expected impact

Likely choppy reaction: upside from Q2 outperformance and buyback flexibility, offset by Q3 net loss guidance and online game revenue decline expectations.

Evidence & confidence

The article discloses specific Q2 revenue and profit figures, a board amendment to extend repurchases open-ended, and explicit Q3 revenue and net loss ranges, which traders can map to estimates and positioning.

Market effects

Provides a datapoint on Chinese online media and game monetization trends, especially marketing services seasonality and online game revenue trajectory.

May influence sentiment toward China ADRs with exposure to online media and gaming demand.

Limited spillover beyond ADR sentiment unless broader China digital media/gaming guidance trends emerge.

Counterpoint

The Q2 GAAP/non-GAAP profitability is boosted by a one-time tax reversal, so underlying operating momentum may be less strong than headline net income suggests.

Key entities

  • Sohu.com Limited

    NASDAQ-listed Chinese online media platform and game business group reporting Q2 2026 results, Q3 guidance, and an amended open-ended ADS repurchase program.

  • Sohu board of directors

    Amended the share repurchase program on Aug 8, 2026 by removing the prior end date and authorizing open-ended repurchases up to the maximum authorized amount.

Related articles

$SOHUMed

3 Low-P/E Stocks That Look Cheap as the S&P 500 Trades Near Record Highs

Sohu.com (SOHU), Onity Group (ONIT), and TriMas (TRS) trade at low P/E ratios (1.6x, 2.3x, 1.6x respectively) despite showing signs of business strength. SOHU reported 7% YOY revenue growth and improved profitability. ONIT saw 24% YOY revenue growth and 64% origination growth but faced servicing headwinds. TRS showed 1.6% YOY sales growth and 29% operating profit increase, with raised earnings guidance.

$SOHUMedAI 8/10

Sohu (SOHU) Q2 2026 Earnings Call Transcript

Sohu.com Limited (SOHU) reported Q2 2026 revenue of $136 million, up 7% YoY but down 4% QoQ. Online games were $116 million, up 10% YoY, while marketing services were $15 million. GAAP net income was $0.2 million after a ~$30 million tax reversal; non-GAAP net income was $0.5 million. The company also said it repurchased 9.4M ADS for ~$124M and authorized more up to $150M. Q3 guidance: marketing services $40M-$50M; online games $105M-$150M.

$SOHUMed

Sohu.com Q2 Earnings Call Highlights

Sohu.com (NASDAQ:SOHU) reported Q2 call highlights, citing sequential growth in marketing services revenue but a weak advertising environment as advertisers stay cautious and shift toward social and influencer-driven marketing. Management forecast Q3 marketing services revenue of $40M-$50M, online game revenue $105M-$115M, and GAAP/non-GAAP net loss of $30M-$23M. Sohu repurchased 9.4M ADS for about $124M, with up to $150M authorized.

$SOHUMed

Sohu.com Ltd (SOHU): Financial results for Q2 2026

Sohu.com Ltd (SOHU) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 SOHU.COM REPORTS SECOND QUARTER 2026 UNAUDITED FINANCIAL RESULTS BEIJING, Aug 10, 2026 –Sohu.com Limited (NASDAQ: SOHU) (“Sohu” or the “Company”), a leading Chinese online media platform and game business group, today reported unaudited financial results for the seco

$AAPLMed

Asia’s Tech Stocks Take the Hit as Apple and Microsoft Push Chip Costs to Consumers

Apple raised MacBook and iPad prices by up to $300 on June 25, citing higher memory and storage chip costs tied to AI data-center demand; its shares closed down more than 6%. Microsoft followed with Xbox price increases of $100–$150 effective Aug. 1; its stock fell 3.5%. The announcements helped drive an Asian selloff, with South Korea’s KOSPI dropping to about 8,600 early, and chip stocks like SK Hynix and Samsung down over 4%.

$IPHAMed

Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript

Innate Pharma (IPHA) reported Q2 2026 earnings, highlighting a cash position of -€21.4M, a $75M upfront payment from Sobi, and -€28M in net equity proceeds. H1 2026 net loss was -€19.6M, with revenue of -€5.7M. The company extended its cash runway to Q1 2028 and anticipates key milestones, including a Phase 3 readout for monalizumab and initial data for IPH4502. Management expects to file for accelerated approval of lacutamab in Sezary Syndrome in H2 2027.